158 related articles for article (PubMed ID: 3015387)
1. Vasoactive intestinal peptide receptor regulation and reversible desensitization in human colonic carcinoma cells in culture.
Boissard C; Marie JC; Hejblum G; Gespach C; Rosselin G
Cancer Res; 1986 Sep; 46(9):4406-13. PubMed ID: 3015387
[TBL] [Abstract][Full Text] [Related]
2. Combined ultrastructural and biochemical study of cellular processing of vasoactive intestinal peptide and its receptors in human colonic carcinoma cells in culture.
Hejblum G; Gali P; Boissard C; Astesano A; Marie JC; Anteunis A; Hui Bon Hoa D; Rosselin G
Cancer Res; 1988 Nov; 48(21):6201-10. PubMed ID: 2844402
[TBL] [Abstract][Full Text] [Related]
3. [Desensitization to VIP by down regulation of its peptide receptors in transformed HT-29 cells of human colonic epithelium in culture].
Boissard C; Hejblum G; Marie JC; Gespach C; Rosselin G
C R Acad Sci III; 1984; 299(19):795-8. PubMed ID: 6099208
[TBL] [Abstract][Full Text] [Related]
4. Importance of the vasoactive intestinal peptide receptor in the stimulation of cyclic adenosine 3',5'-monophosphate in gallbladder epithelial cells of man. Comparison with the guinea pig.
Dupont C; Broyart JP; Broer Y; Chenut B; Laburthe M; Rosselin G
J Clin Invest; 1981 Mar; 67(3):742-52. PubMed ID: 6259209
[TBL] [Abstract][Full Text] [Related]
5. Vasoactive intestinal peptide receptor/adenylate cyclase system: differences between agonist- and protein kinase C-mediated desensitization and further evidence for receptor internalization.
Turner JT; Bollinger DW; Toews ML
J Pharmacol Exp Ther; 1988 Nov; 247(2):417-23. PubMed ID: 2846820
[TBL] [Abstract][Full Text] [Related]
6. Vasoactive intestinal polypeptide inhibits c-myc expression and growth of human gastric carcinoma cells.
Kim SW; Beauchamp RD; Townsend CM; Thompson JC
Surgery; 1991 Aug; 110(2):270-5; discussion 276. PubMed ID: 1713357
[TBL] [Abstract][Full Text] [Related]
7. Characterization of vasoactive intestinal peptide receptors in human colonic epithelial cells.
Broyart JP; Dupont C; Laburthe M; Rosselin G
J Clin Endocrinol Metab; 1981 Apr; 52(4):715-21. PubMed ID: 6259191
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
[TBL] [Abstract][Full Text] [Related]
9. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
[TBL] [Abstract][Full Text] [Related]
10. [Vasoactive intestinal peptide receptor in a human pancreatic carcinoma cell line].
Chen Y
Zhonghua Yi Xue Za Zhi; 1990 Mar; 70(3):135-7, 12. PubMed ID: 2163737
[TBL] [Abstract][Full Text] [Related]
11. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors.
Virgolini I; Yang Q; Li S; Angelberger P; Neuhold N; Niederle B; Scheithauer W; Valent P
Cancer Res; 1994 Feb; 54(3):690-700. PubMed ID: 7905785
[TBL] [Abstract][Full Text] [Related]
12. Restricted localization of functional vasoactive intestinal peptide (VIP) receptors in in vitro differentiated human colonic adenocarcinoma cells (HT29-D4).
Fantini J; Martin JM; Luis J; Rémy L; Tirard A; Marvaldi J; Pichon J
Eur J Cell Biol; 1988 Aug; 46(3):458-65. PubMed ID: 2846304
[TBL] [Abstract][Full Text] [Related]
13. Properties of vasoactive intestinal peptide-receptor interaction in rat liver membranes.
Guerrero JM; Prieto JC; Ramírez-Cárdenas R; Calvo JR; Goberna R
Rev Esp Fisiol; 1981 Mar; 37(1):1-8. PubMed ID: 6113623
[TBL] [Abstract][Full Text] [Related]
14. Vasoactive intestinal peptide control of cyclic adenosine 3':5'-monophosphate levels in seven human colorectal adenocarcinoma cell lines in culture.
Laburthe M; Rousset M; Chevalier G; Boissard C; Dupont C; Zweibaum A; Rosselin G
Cancer Res; 1980 Jul; 40(7):2529-33. PubMed ID: 6248206
[TBL] [Abstract][Full Text] [Related]
15. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
Zawilska JB; Niewiadomski P; Nowak JZ
Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
[TBL] [Abstract][Full Text] [Related]
16. Functional receptors for vasoactive intestinal peptide on human osteosarcoma cells.
Hohmann EL; Tashjian AH
Endocrinology; 1984 Apr; 114(4):1321-7. PubMed ID: 6323142
[TBL] [Abstract][Full Text] [Related]
17. Molecular identification and structural requirement of vasoactive intestinal peptide (VIP) receptors in the human colon adenocarcinoma cell line, HT-29.
Couvineau A; Rousset M; Laburthe M
Biochem J; 1985 Oct; 231(1):139-43. PubMed ID: 2998337
[TBL] [Abstract][Full Text] [Related]
18. Serine 447 in the carboxyl tail of human VPAC1 receptor is crucial for agonist-induced desensitization but not internalization of the receptor.
Marie JC; Rouyer-Fessard C; Couvineau A; Nicole P; Devaud H; El Benna J; Laburthe M
Mol Pharmacol; 2003 Dec; 64(6):1565-74. PubMed ID: 14645688
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of vasoactive intestinal peptide (VIP) binding on human melanoma cells IGR39 by nitric oxide: cGMP is not involved.
Fouchier F; Pichon J; Forget P
Eur J Cell Biol; 1994 Jun; 64(1):71-7. PubMed ID: 7957315
[TBL] [Abstract][Full Text] [Related]
20. Vasoactive intestinal peptide- and adrenocorticotropin-stimulated adenyl cyclase in cultured adrenal tumor cells: evidence for a specific vasoactive intestinal peptide receptor.
Birnbaum RS; Alfonzo M; Kowal J
Endocrinology; 1980 Apr; 106(4):1270-5. PubMed ID: 6244149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
